1[1]Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to Gefinitib therapy[DB/OL]. Science, 29 April 2004 [Dol: 10. 1126/science.1099314].
2[3]Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib [J]. N Engl J Med,2004,350(21 ): 2129-2139.
3[4]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oneol, 2003,21: 2237-2246.
4[5]Kris MG, Natale RS, Herbst RS, et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor tyrosine kinase,in symptomatic patients with non-small-cell lung cancer: a randomized trial [J]. JAMA, 2003,290:2149-2158.
5[6]Simon GR, Ruckdeschel JC, Williams C, et al. Gefitinib(ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution [J ]. Cancer Control,2003,10(5) :388-395.
6[7]Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with Gefitinib (ZD1839, ‘Iressa') on an expanded access study [J].Lung Cancer, 2004,44 (2): 221-230.
7Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase Ⅰ trial. J
8Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol, 2002,29
9Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 1. J Clin Oncol,2004,22(5):777-784.
10Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res,2002,8(10): 3250-3258.
